Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
60

Summary

Conditions
  • Pain
  • Sickle Cell Disease
Type
Interventional
Phase
Phase 1Phase 2
Design
Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment

Participation Requirements

Age
Between 12 years and 65 years
Gender
Both males and females

Description

Patients will be randomized to a single dose of IVIG versus normal saline placebo during an uncomplicated pain crisis. Length of VOC and other secondary endpoints will be monitored.

Patients will be randomized to a single dose of IVIG versus normal saline placebo during an uncomplicated pain crisis. Length of VOC and other secondary endpoints will be monitored.

Tracking Information

NCT #
NCT01757418
Collaborators
Not Provided
Investigators
Principal Investigator: Deepa G Manwani, M.D Albert Einstein College of Medicine